On Nov. 19, MIT Technology Review unveiled its list of "50 Smartest Companies" (TR50) of 2020 in Suzhou, China. Thanks to the innovative breakthroughs in oligonucleotide therapeutics, Ribo was shortlisted as a manufacturer of innovative drugs and listed as a TR50 smart company.

For 10 consecutive years, the MIT Technology Review has been searching for "smart companies" with core strengths in emerging technologies globally to create its TR50 annual list. The deepening focus on China beginning in 2019 has caught the attention of many. The year 2020 is a 10-year milestone for MIT Technology Review and is notable in many ways. The global review committee of MIT Technology Review once again focused on "China cohesion" as it maintained its attention on the country. Besides focusing on innovative breakthroughs in emerging technologies, the TR50 review committee also considers the companies' value of superior business acumen and major innovations that will redefine their field.

Ribo will continue to build and improve its platform system of a complete oligonucleotide pharmaceutical industrial chain, actively explore key innovative technologies of oligonucleotide therapeutics, and continue to promote innovation of oligonucleotide therapeutics to bring more accurate and efficient therapies to patients and make China's oligonucleotide therapeutics serve the world.